Kosuke Hamai

464 total citations
32 papers, 279 citations indexed

About

Kosuke Hamai is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Kosuke Hamai has authored 32 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Kosuke Hamai's work include Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Lung Cancer Research Studies (9 papers). Kosuke Hamai is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Lung Cancer Research Studies (9 papers). Kosuke Hamai collaborates with scholars based in Japan, United States and Norway. Kosuke Hamai's co-authors include Nobuhisa Ishikawa, Noboru Hattori, Hiroshi Iwamoto, Kazunori Fujitaka, Hironobu Hamada, Yasushi Horimasu, Shinichiro Ohshimo, Takeshi Masuda, Nobuoki Kohno and Shintaro Miyamoto and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Anti-Cancer Drugs.

In The Last Decade

Kosuke Hamai

28 papers receiving 275 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kosuke Hamai Japan	9	203	84	47	41	29	32	279
Ryoichi Honda Japan	8	50 0.2×	82 1.0×	5 0.1×	38 0.9×	6 0.2×	26	183
Malai Wongchanchailert Thailand	11	41 0.2×	21 0.3×	62 1.3×	40 1.0×	42 1.4×	34	350
Kanak Parmar United States	6	48 0.2×	55 0.7×	11 0.2×	28 0.7×	4 0.1×	30	167
Nabil Kabbara France	8	62 0.3×	91 1.1×	14 0.3×	46 1.1×	56 1.9×	14	386
Mariagrazia Garzia Italy	8	20 0.1×	51 0.6×	12 0.3×	14 0.3×	17 0.6×	19	201
K Nishikawa Japan	7	32 0.2×	76 0.9×	6 0.1×	23 0.6×	15 0.5×	27	187
Hideki Kusagaya Japan	9	197 1.0×	42 0.5×	115 2.4×	64 1.6×	65 2.2×	21	362
Dolly Kervitsky United States	6	334 1.6×	12 0.1×	103 2.2×	46 1.1×	43 1.5×	9	391
Gloria Pérez‐Rus Spain	7	22 0.1×	33 0.4×	10 0.2×	12 0.3×	22 0.8×	14	214
A. Ali Zirakzadeh Sweden	8	27 0.1×	161 1.9×	7 0.1×	52 1.3×	17 0.6×	13	300

Countries citing papers authored by Kosuke Hamai

Since Specialization

Citations

This map shows the geographic impact of Kosuke Hamai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kosuke Hamai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kosuke Hamai more than expected).

Fields of papers citing papers by Kosuke Hamai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kosuke Hamai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kosuke Hamai. The network helps show where Kosuke Hamai may publish in the future.

Co-authorship network of co-authors of Kosuke Hamai

This figure shows the co-authorship network connecting the top 25 collaborators of Kosuke Hamai. A scholar is included among the top collaborators of Kosuke Hamai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kosuke Hamai. Kosuke Hamai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nakashima, Kazuhisa, Haruyasu Murakami, Toshiaki Takahashi, et al.. (2024). Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status. Respiratory Investigation. 62(6). 1137–1141.

Hamai, Kosuke, et al.. (2024). A Retrospective Analysis of the Efficacy of Oral Dexamethasone in Combination With Docetaxel Plus Ramucirumab Therapy for Previously Treated Lung Cancer. Cancer Control. 31. 2925692663–2925692663.

Tsuyuki, Yoshiaki, et al.. (2024). Anti-OJ Antibody-positive Antisynthetase Myopathy Diagnosed after Pulmonary Embolization. Internal Medicine. 64(11). 1750–1755.

Hirano, Katsuya, Akito Hata, Toshiyuki Sumi, et al.. (2024). Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs) for extensive disease small-cell lung cancer (ED-SCLC).. Journal of Clinical Oncology. 42(16_suppl). 8097–8097. 1 indexed citations

Hamai, Kosuke, Sayaka Ueno, Ken Masuda, et al.. (2023). Comprehensive genomic profiling of Japanese patients with thoracic malignancies: A single-center retrospective study. Respiratory Investigation. 61(6). 746–754. 3 indexed citations

Hamai, Kosuke, et al.. (2023). Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer. Cancer Reports. 6(4). e1793–e1793. 1 indexed citations

Tsubata, Yukari, Kosuke Hamai, Naoki Furuya, et al.. (2022). Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data. International Journal of Clinical Oncology. 28(1). 69–78. 11 indexed citations

Yamaguchi, Kakuhiro, Hiroaki Terada, Kosuke Hamai, et al.. (2022). Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer. BMC Pulmonary Medicine. 22(1). 260–260. 4 indexed citations

Ueno, Sayaka, Kosuke Hamai, Naoki Tsuji, et al.. (2022). Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study. Respiratory Investigation. 60(3). 418–424. 2 indexed citations

10.

Tanaka, Kentaro, Hajime Asahina, Junji Kishimoto, et al.. (2021). Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. European Journal of Cancer. 149. 14–22. 35 indexed citations

11.

Ishikawa, Nobuhisa, Kosuke Hamai, Hiroki Kobayashi, et al.. (2021). Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world settings: A retrospective observational study. Respiratory Investigation. 59(4). 478–486. 15 indexed citations

12.

Tsubata, Yukari, Takeshi Masuda, Kosuke Hamai, et al.. (2021). Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor‐mutant non‐small cell lung cancer: A prospective, multicenter, dose‐modification study. Geriatrics and gerontology international. 21(10). 881–886. 6 indexed citations

13.

Hamai, Kosuke, Kazunori Fujitaka, Yasushi Horimasu, et al.. (2021). Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB/IV squamous cell lung cancer: a phase II study. Anti-Cancer Drugs. 32(7). 767–772. 2 indexed citations

14.

Hotta, T, Yukari Tsubata, Kosuke Hamai, et al.. (2020). Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism. Respiratory Investigation. 59(3). 327–334. 4 indexed citations

15.

Hamai, Kosuke, et al.. (2019). Treatment of ALK-positive Lung Cancer with Crizotinib-derived Complexed Renal Cysts Using Alectinib and Ceritinib: a Case Study. Haigan. 59(3). 260–264.

16.

Hamai, Kosuke, Hiroshi Iwamoto, Shinichiro Ohshimo, et al.. (2018). Use of proton pump inhibitors is associated with increased mortality due to nosocomial pneumonia in bedridden patients receiving tube feeding. Geriatrics and gerontology international. 18(8). 1215–1218. 8 indexed citations

17.

Yamaguchi, Kakuhiro, Takeshi Masuda, Kazunori Fujitaka, et al.. (2018). Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study. In Vivo. 32(5). 1155–1160. 6 indexed citations

18.

Okada, Morihito, Kentaro Tanaka, Hajime Asahina, et al.. (2018). Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with non–small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR.. Journal of Clinical Oncology. 36(15_suppl). e21073–e21073. 11 indexed citations

19.

Horimasu, Yasushi, Nobuhisa Ishikawa, Masaya Taniwaki, et al.. (2017). Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets. BMC Medical Genetics. 18(1). 88–88. 27 indexed citations

20.

Hamai, Kosuke, et al.. (2009). [Case of pulmonary dirofilariasis with cavity formation in a young woman].. PubMed. 47(5). 372–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact